2. Disease Areas
  3. Infection
  4. Coronavirus Infection
  5. hCoV-229E

hCoV-229E

hCoV-229E is an alphacoronavirus closely related to HCoV-NL63, belonging to the subfamily Orthocoronavirinae, which comprises several zoonotic viruses. It commonly circulates alongside other strains and genotypes, primarily causing respiratory infections in humans.

hCoV-229E (4):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-161356
    BPR3P0128 1345406-09-8 98.58%
    BPR3P0128 is an orally active, non-nucleoside RNA-dependent RNA polymerase (RdRp) inhibitor that has been shown to inhibit the activity of various SARS-CoV-2 variants. The EC50 for SARS-CoV-2 and HCoV-229E are 0.62 μM and 0.14 μM. BPR3P0128 demonstrates effective anti-pancoronavirus activity within the submicromolar range. PR3P0128 shows synergistic antiviral activity when combined with Remdesivir (HY-104077).
    BPR3P0128
  • HY-178696
    UAWJ9-36-3 2663864-31-9
    UAWJ9-36-3 is a Mpro and cathepsin L (IC50: 1.81 μM) inhibitor. UAWJ9-36-3 shows potent binding and enzymatic inhibition against the Mpros from SARS-CoV-2, SARS-CoV, MERS-CoV, HCoV-OC43, HCoV-NL63, HCoV-229E, and HCoV-HKU1. UAWJ9-36-3 demonstrates broad-spectrum antiviral activity against not only SARS-CoV-2, but also the common human coronaviruses HCoV-OC43, HCoV-NL63, and HCoV-229E.
    UAWJ9-36-3
  • HY-122668
    K22 2141978-86-9 98.46%
    K22 is an anti-Coronaviral compound. K22 reduces double-stranded RNA. K22 displays antiviral activity beyond the Coronavirinae subfamily, namely against nidoviruses of the Torovirinae subfamily (EToV and WBV) and members of the Arteriviridae family (PRRSV, EAV). K22 displays antiviral activity against HCoV-229E.
    K22
  • HY-183761
    Antiviral agent 86
    Antiviral agent 86 is an anti-coronavirus agent. Antiviral agent 86 acts as a binder of coronavirus non-structural protein 15 (nsp15), with a Ka value of 67 μM against human targets. Antiviral agent 86 inhibits the replication of HCoV-229E and SARS-CoV-2. Antiviral agent 86 exerts inhibitory effects at the post-entry lifecycle stage of coronaviruses in host cells and inhibits the formation of viral double-stranded RNA (dsRNA). Antiviral agent 86 exhibits an additive antiviral effect when used in combination with GS-441524. Antiviral agent 86 can be used in studies related to coronavirus infections.
    Antiviral agent 86